Miller K, Wang M, Gralow J, et al

0 Comments

Miller K, Wang M, Gralow J, et al. same time, it would make little sense to have an agent that reduces chances of dying of malignancy but increases off-target deaths; hence, the need for verification of OS. Phase III trials that statement on significant PFS benefits without OS prolongation become the apples of discord in […]